AOD 9604 is available for research and laboratory purposes only
Acknowledgments Authors want to thank Germaine Pugh and Cassia McClain for their invaluable help in preparing the manuscript
Exploring reported data from international initiatives such as the Covenant of May without proper monitoring and contrasting it with detailed information about particular implementation processes reveals important information for the science community and practitioners, which can contribute to closing the gap between planning and implementation
Consider whether symptoms might indicate: Underlying conditions being unmasked or worsening Effects of other supplements or medications Lifestyle factors like inadequate sleep, poor nutrition, or excessive stress Infections or illnesses unrelated to peptide use If symptoms do not match the expected AOD 9604 profile, persist after discontinuation, or are accompanied by other concerning signs, investigate independently rather than assuming the peptide is responsible
Mechanistically, tirzepatide + 5-amino-1MQ should outperform semaglutide monotherapy, but individual response variability and lack of head-to-head data prevent definitive claims
Primary Compound: delta sleep-inducing peptide , or simply dsip delta sleep inducing peptide